Be Prepared to Treat and Prevent VTE Due to Cancer

June 2020

You’ll continue to see a shift toward direct oral anticoagulants (Eliquis, etc) for cancer-associated venous thromboembolism (VTE).

For years, we’ve been using a low-molecular-weight heparin (LMWH), such as enoxaparin...with warfarin as an alternative.

But evidence with DOACs is stacking up for VTE due to cancer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote